Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
What is your approach to isolated thoracic recurrence of NSCLC in an otherwise asymptomatic patient with prior chemoradiation and immunotherapy?
Do you routinely recommend repeat biopsy to confirm recurrence?
Related Questions
At what age do you stop LDCT chest for lung cancer screening?
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
Would you consider starting immunotherapy in a patient with stage IV NSCLC, a high PDL1 level, and active, untreated hepatitis C?
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Would a patient with a resected NSCLC mass under 3 cm, without lymph node involvement or distant metastases, but with visceral invasion identified on pathology, benefit from adjuvant therapy?
Do you tell your patients with epithelioid subtype mesothelioma following gross resection and adjuvant cis/pemetrexed that they have completed "curative intent" treatment?